Strand Genomics Inc. Appoints Corporate Thought Leader Ravi Venkatesan to its Board of Directors
ROCKVILLE, Md., May 23, 2014 /PRNewswire/ — Strand Genomics Inc., a new generation healthcare innovation company headquartered in Bangalore, India, today announced that Ravi Venkatesan, the Chairman of Microsoft India from 2004-2011 who helped to build and expand Microsoft’s position in India as the company’s largest presence outside of the U.S., has joined the Strand Board of Directors. Mr. Venkatesan is the author of the acclaimed Conquering the Chaos: Win in India, Win Everywhere, published by HBR and is currently the founding chairman of the Social Ventures Partners, India. He serves as a director on the Boards of Infosys and AB Volvo.
“The advances in genomics are greatly complemented by those of computer science,” said Ravi Venkatesan. “The future of cancer screening, diagnostics, and screening for genetic predispositions is being transformed by the melding of the science of genomics with information technology. Strand is among the world leaders in this important transformative arena.”
Mr. Venkatesan has held multiple senior leadership positions. In addition to his former role at Microsoft India, he was formerly the Chairman of Cummins India. He holds a B.S. in engineering from IIT Bombay, an M.S. from Purdue University, and an M.B.A. from Harvard Business School where he was a Baker Scholar. He was voted as the most influential MNC CEO by the Economic Times in 2011. He was also voted as one of India’s best management thought leaders by Thinkers50.
With regard to his appointment to Strand’s Board, Mr. Venkatesan stated, “It is my pleasure to join the innovation leader in personalized medicine using genomics. In the past year, Strand has begun to commercialize its software platform and testing services for clinical use. The company will play an increasingly important role going forward for India and the rest of the world.”
Dr. Vijay Chandru, Chairman and CEO of Strand, said, “We are delighted to have Ravi Venkatesan join our Board of Directors at a crucial junction when the company has strategized for exponential growth in the individualized medicine space. Ravi brings a wealth of experience that facilitates the company’s capabilities as a global leader in clinical genomics.”
About Strand Genomics Inc.
Founded in 2000, Strand Genomics Inc. is a leader in technology innovations for healthcare using genomics. Strand’s entry into healthcare was through software products and services that combine advanced visualization, systems modeling, and scientific insights for enabling biological and health sciences research. Over 1400 institutions worldwide (about 30% of global market share) and 100 hospitals benefit from Strand’s technology products and services today, including several leading clinical research institutions, pharmaceutical and biotechnology companies. With a highly skilled workforce of over 200 computer and life scientists, Strand has set up three clinical and translational research laboratories in Bangalore that are enabled with the cutting-edge Next Generation Sequencing (NGS) technologies. Strand is a portfolio company of Biomark Capital Partners, a San Francisco based global fund for health and life sciences. By enabling DNA sequence-based diagnostics and clinical genomic data interpretation using a strong foundation of computational, scientific, and medical expertise, Strand is bringing individualized medicine to the world.
SOURCE Strand Genomics, Inc.